SOHM, Inc. Shares Outlook for the Year 2023 and Progress On its Manufacturing Facility and Other Projects.
CHINO HILLS, Calif. / — March 2, 2023 – SOHM, Inc. (Pink Sheets: SHMN) (the “Company”), a generic pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering various treatment categories, announces today some important revises.
Mr. Baron Night, CEO, stated that the company has identified and working on various priorities for the company’s long-term goals.
Revenue growth is a key performance indicator for any business, as it reflects the company’s ability to generate income and increase profitability. The company aim to have higher revenue growth. It can be achieved through various organic, in-organic vertical strategies, such as increasing sales, expanding into new markets, introducing new products or services, and improving operational efficiency.
The company’s core and long-term priorities are:
- Making the manufacturing facility at San Diego operational and for it, the company has been awaiting a few more machineries and equipment. The management anticipate the equipment and machineries to arrive by end of this quarter or early second quarter. The management is very keen on making it running and operational as stated earlier.
- The facility will have all three major divisions/sections starting with setting up manufacturing of its Topical products, followed by Capsules and last phase is Tablets division.
- The management is also working towards nutraceutical products in line with its various preventive health sectors.
- The management has identified its nine topical prescriptions (Rx) and OTC products manufacturing & distribution of products in skincare segments and are in process of getting the orders from our distributor partners. They’ll be in SOHM label products.
- The earlier disclosed funding actions are going on but has got delayed due to various reasons but and we anticipate outcome in mid or end of 2nd quarter. The management doesn’t see any issues with it and all the priorities will go smoothly with or without the funding as disclosed earlier.
- The distribution company’s acquisition as previously announced is on hold or likely to get cancelled by us as currently target company has some legal challenges.
Mr. Baron Night, CEO said that SOHM can finish its targeted current projects efficiently, as shared earlier. The Company plans to update its stakeholders about the new important pipeline projects which will significantly change the future of the company.
The company’s leadership and management assure confidently to its stakeholders that it is confident in achieving its goals and objectives. The management and staff are working relentlessly to build trust and confidence among investors, customers, and all stakeholders, Mr. Baron Night CEO added.
About SOHM, Inc.
SOHM, Inc. is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing, targets the rapidly growing healthcare segments, such as nutraceuticals, cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America, with manufacturing alliances in India and strategic partnerships/alliances with U.S. manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To learn more about SOHM, Inc., visit www.SOHM.com.
Safe Harbor Statement:
This news release contains “forward-looking statements,” which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
For more information, please contact:
SOHM, Inc.
714-522-6700